Last Updated: November 17, 2026

CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M TETROFOSMIN KIT

« Back to Dashboard


All Clinical Trials for technetium tc-99m tetrofosmin kit

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01397994 ↗ Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status Ferozsons Laboratories Ltd. Phase 4 2011-09-01 This study is to determine the anti-anginal and anti-ischemic effect of k-channel opener, nicorandil in patients of chronic stable angina.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for technetium tc-99m tetrofosmin kit

Condition Name

Condition Name for technetium tc-99m tetrofosmin kit
Intervention Trials
Chronic Stable Angina 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for technetium tc-99m tetrofosmin kit
Intervention Trials
Angina, Stable 1
Angina Pectoris 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for technetium tc-99m tetrofosmin kit

Trials by Country

Trials by Country for technetium tc-99m tetrofosmin kit
Location Trials
Pakistan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for technetium tc-99m tetrofosmin kit

Clinical Trial Phase

Clinical Trial Phase for technetium tc-99m tetrofosmin kit
Clinical Trial Phase Trials
Phase 4 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for technetium tc-99m tetrofosmin kit
Clinical Trial Phase Trials
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for technetium tc-99m tetrofosmin kit

Sponsor Name

Sponsor Name for technetium tc-99m tetrofosmin kit
Sponsor Trials
Ferozsons Laboratories Ltd. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for technetium tc-99m tetrofosmin kit
Sponsor Trials
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial
Last updated: July 30, 2026

Technetium Tc-99m Tetrofosmin Kit Clinical Trials Update, Market Analysis, and Price-Erosion Projection (2026-2035)

Executive summary: No public, sourceable clinical-trials update or current FDA market exclusivity and Orange Book patent exposure can be compiled from the provided inputs. A complete, accurate trials-and-projection brief requires drug-specific trial registries, FDA review milestones, and exclusivity/patent status tied to the specific branded kit(s) and NDA/ANDA/BLA. With only the product name and no linked sponsor, NDA/ANDA number, or brand/manufacturer, a high-stakes projection would be incomplete.

What clinical trials exist for Technetium Tc-99m tetrofosmin kit in 2024–2026?

Featured snippet answer: A definitive 2024–2026 clinical-trials update cannot be compiled without the specific branded kit, sponsor, and FDA application identifiers.

Which trial registries must be reviewed for Tc-99m tetrofosmin kits?

  • ClinicalTrials.gov (interventional and observational studies)
  • EU Clinical Trials Register (EudraCT)
  • Sponsor publications and investigator-initiated studies

What endpoints typically drive Tc-99m tetrofosmin trials?

  • Myocardial perfusion imaging diagnostic performance (sensitivity/specificity vs reference tests)
  • Radiation dosimetry and image quality metrics
  • Comparative imaging with alternative tracers and/or SPECT protocols
  • Stress modality comparisons (exercise vs pharmacologic)

Is Technetium Tc-99m tetrofosmin kit under exclusivity, and what is the Orange Book status?

Featured snippet answer: Orange Book status cannot be determined from the product name alone.

What to look for in the Orange Book for radiopharmaceutical kits

  • Listing type (drug product and/or method patents)
  • Active ingredient form and kit configuration
  • Associated NDA number(s)
  • Patent expiry and term-adjustment/extension

Exclusivity categories relevant to radiopharmaceuticals

  • 5-year new chemical entity (NCE) or new radiopharmaceutical approvals, if applicable
  • 3-year new clinical investigation exclusivity tied to specific data packages
  • Pediatric exclusivity extensions, if any
  • Pediatric Rare Disease Priority Review vouchers are not applicable in a standard way, but pediatric exclusivity can affect launch timing

What patents protect Technetium Tc-99m tetrofosmin kit and its imaging methods?

Featured snippet answer: A patent estate cannot be enumerated accurately without the underlying NDA/ANDA and specific branded kit(s).

Typical patent clusters for myocardial perfusion agents

  • Radiochemical formulation and kit stability
  • Radiolabeling process parameters
  • Method-of-use claims (stress perfusion imaging in CAD)
  • Imaging protocol claims (timing, dosimetry, imaging system parameters)
  • Manufacturing methods and impurity controls

How many patents cover Tc-99m tetrofosmin kits?

  • Requires Orange Book harvest by NDA and then mapping to:
    • Drug substance vs drug product
    • Formulation vs method-of-use
    • Any terminal disclaimers affecting real expiry

When does Technetium Tc-99m tetrofosmin kit lose exclusivity and face generic or kit-entry risk?

Featured snippet answer: Launch timing cannot be projected without verified exclusivity/patent expiry by specific NDA/marketed kit.

What determines real-world entry barriers

  • Shelf-life and storage constraints that affect kit distribution economics
  • Radiopharmacy cold-chain logistics and regional supply contracts
  • Radiolabel yield, specific activity, and QC release times
  • Broker and distributor channels for hospital systems

What Paragraph IV challenges exist for Tc-99m tetrofosmin kits, and which companies are litigating?

Featured snippet answer: Paragraph IV litigation cannot be confirmed without knowing the NDA/ANDA identifiers and Orange Book listings.

What filings matter

  • ANDA Paragraph IV certifications (if the regulatory pathway exists for the kit)
  • District court dockets and settlement agreements
  • Generic/competitor launch outcomes tied to injunctions or non-infringement rulings

How does Technetium Tc-99m tetrofosmin compare with Tc-99m sestamibi and other myocardial perfusion tracers on evidence and economics?

Featured snippet answer: Comparative clinical and market analysis cannot be quantified in this brief without validated trial comparisons and market share baselines for each tracer.

Comparators that drive hospital formulary decisions

  • Tc-99m sestamibi (myocardial perfusion)
  • Stress-only vs rest-stress protocols
  • Alternative agents (depending on availability and reimbursement)

What to measure for a fair comparison

  • Diagnostic performance parity for CAD detection and ischemia localization
  • Post-processing requirements for SPECT/CT or dedicated cardiac cameras
  • Supply reliability and pricing volatility (generator and isotope supply chain)

What is the current market size and forecast for Technetium Tc-99m tetrofosmin kits?

Featured snippet answer: A credible market forecast cannot be produced from the product name alone because the forecast must anchor to:

  • specific branded kit(s) and manufacturers,
  • unit volumes and dosing conventions by labeling,
  • geography (US vs EU vs other regions),
  • reimbursement and contracting structures,
  • and isotope supply trends that affect pricing.

Market drivers specific to Tc-99m radiopharmaceutical kits

  • Isotope availability (Mo-99/Tc-99m generator supply)
  • Hospital imaging utilization trends (outpatient vs inpatient)
  • Imaging reimbursement rates and prior authorization patterns
  • Competitive replacement by other tracers

Market constraints

  • Regulatory and QA release delays
  • Lead times for radiochemical manufacturing and testing
  • Hospital formulary churn cycles

What is the 2026–2035 revenue projection and price-erosion scenario for Tc-99m tetrofosmin kits?

Featured snippet answer: A price-erosion projection cannot be responsibly quantified without known market entry and patent/exclusivity timelines tied to specific branded kits and confirmed competitors.

Scenario framework that must be anchored to verified dates

  • Base case: no new entrants until after verified exclusivity expiry
  • Patent settlement: delayed entry after a term-specific trigger
  • Early entry: at-risk launch following adverse injunction outcomes
  • Contract-driven discounting: hospital group purchasing and distributor margin compression

What financial variables must be sourced

  • Average selling price by geography and pack size
  • Dose counts per kit and reconstitution losses
  • Returns and wastage rates (shelf-life and on-hand inventory)
  • Distributor fees and wholesaler markups

What manufacturing and IP barriers could block generic or kit-entry for Tc-99m tetrofosmin?

Featured snippet answer: Barriers can include formulation stability, radiochemical specification limits, and method-of-use IP, but their actual impact needs a mapped patent and regulatory entry plan.

Quality and release factors that affect comparability

  • Radiochemical purity and impurity profiles
  • Labeling efficiency and specific activity ranges
  • Stabilizer composition and kit shelf-life

How IP can extend beyond the core formulation

  • Process patents can block manufacturing even with a bioequivalent tracer
  • Method-of-use patents can restrict clinical adoption or force carve-outs

Key Takeaways

No sourceable, drug-specific clinical-trials update, exclusivity/Orange Book status, patent estate mapping, or 2026–2035 market and price-erosion projection can be produced from “Technetium Tc-99m tetrofosmin kit” alone. High-stakes forecasting requires tying the analysis to specific branded kit(s), NDA/ANDA identifiers, and confirmed clinical-trials and litigation records.

FAQs

  1. Which ClinicalTrials.gov studies are recruiting or active for Tc-99m tetrofosmin myocardial perfusion imaging in 2025?
  2. What are the latest court rulings involving Tc-99m tetrofosmin kit patents or method-of-use claims?
  3. What is the Orange Book listing for Tc-99m tetrofosmin kits, and when do the latest patents expire?
  4. How does Mo-99/Tc-99m supply risk affect the pricing and availability of tetrofosmin kits?
  5. What hospital formulary trends determine utilization of tetrofosmin versus sestamibi in the US and EU?

References

  1. ClinicalTrials.gov. (n.d.). [Database]. https://clinicaltrials.gov
  2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
  3. FDA. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
  4. FDA. (n.d.). Radiopharmaceutical and imaging drug regulatory resources. https://www.fda.gov/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.